Boehringer Ingelheim
May need wider eczema caution for kids: FDA
...five-disease vaccine Pentacel; diphtheria, tetanus and pertussis vaccine Daptacel * Privately held Boehringer Ingelheim's HIV drug Viramune (nevirapine) * Glaxo's...
US FDA staff: may need wider eczema caution for kids
...five-disease vaccine Pentacel; diphtheria, tetanus and pertussis vaccine Daptacel * Privately held Boehringer Ingelheim's HIV drug Viramune (nevirapine) * Glaxo's rotavirus...
JavaScript and Flash are required to fully enjoy Evri
Merck blood thinner appears safe, effective
...by several drugmakers, including Bayer, Bristol-Myers Squibb Co in partnership with Pfizer Inc, and Boehringer Ingelheim. While Merck is well behind rivals, analysts have...
UPDATE 1-Merck blood thinner appears safe, effective-study
...including Bayer <BAYGn. DE>, Bristol-Myers Squibb Co <BMY.N> in partnership with Pfizer Inc <PFE.N>, and Boehringer Ingelheim. While Merck is well behind rivals, analysts have...
Reportlinker Adds Global Chronic Obstructive Pulmonary Disease Industry
...2015. The report profiles 53 companies including many key and niche players worldwide such as AstraZeneca Plc, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Novartis AG, Nycomed S.C.A....
Evotec Signs High Throughput Screening Agreement With Active Biotech
...and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. Evotec has...
Evotec Reports Good Progress in Product Development in Treatment-Resistant Depression in its Alliance With Roche
...with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche.
Exelixis, Inc. Q4 2009 Earnings Call Transcript
...business development efforts and find a major collaboration with Sanofi-Aventis as well as a collaboration with Boehringer Ingelheim, which brought in substantial cash. Compared to 2008,...
"We are committed to providing effective treatment options that may help ease the burden of Parkinson's disease, and the MIRAPEX ER approval is very exciting," said Albert Ros, executive vice president, Boehringer Ingelheim Pharmaceuticals, Inc. "The Parkinson's community now has an important new treatment option with benefits similar to the currently available immediate-release formulation."
FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease PR Newswire: Health / Biotech | 3 weeks ago
Generic drugmaker Teva names Frost as chairman
...of the drug. The settlement allowed Impax to launch the generic tamsulosin hydrochloride on Tuesday. Boehringer Ingelheim developed the drug and markets it with Astellas. Executives at...
Pfizer, Bristol-Myers Blood Thinner Stops Clots After Surgery
...and died, and it's not clear if the drug played a role, the researchers said. Johnson & Johnson, Bayer AG and Boehringer Ingelheim GmbH sell similar drugs to prevent blood clots in...
Pfizer, BMS anti-clot drug promising in new trial
...number of new oral anticoagulants hoping to unseat Sanofi-Aventis's <SASY.PA> Lovenox. It will compete with Boehringer Ingelheim's Pradaxa and another drug called Xarelto from Bayer...
Exelixis Announces March 10 Webcast of Presentation at the Cowen and Company 30th Annual Healthcare Conference
...Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, Pfizer Inc., and Daiichi-Sankyo. For more information,...
